# DAFTAR PUSTAKA


1. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemporary Oncology/Współczesna Onkologia. 2021 Feb 23;25(1):45-52.

2. Jusuf A, Wibawanto A, Ichsan AG, Syahruddin E, Juniarti, Endardjo S. Kanker Paru. Perhimpunan Dokter Indonesia. 2018.

3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-249. doi:10.3322/caac.21660

4. Nasim F, Sabath BF, Eapen GA. Lung Cancer. *Med Clin North Am*. 2019;103(3):463-473. doi:10.1016/j.mcna.2018.12.006

5. Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-Based lung cancer screening: A systematic review. *Lung Cancer*. 2020;147(April):154-186. doi:10.1016/j.lungcan.2020.07.007

6. Alevizakos, M., Kaltsas, S. & Syrigos, K.N. The VEGF pathway in lung cancer. *Cancer Chemother Pharmacol* 72, 1169–1181 (2013). https://doi.org/10.1007/s00280-013-2298-3

7. Roy H, Bhardwaj S, Ylä-Herttuala S. Biology of vascular endothelial growth factors. FEBS letters. 2006 May 22;580(12):2879-87.

8. JH, Shao Y, Wang JJ, Li YL, Yang HQ, Liu J, Yang Y. Evaluation of diagnostic and predictive values of the serum VEGF-A level and systemic immune-inflammation index in small cell lung cancer. Journal of Cancer. 2021;12(5):1356.

9. Matsuyama W, Hashiguchi T, Mizoguchi A, Iwami F, Kawabata M, Arimura K, Osame M. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest. 2000 Oct 1;118(4):948-51.

10. Cao C, Sun SF, Lv D, Chen ZB, Ding QL, Deng ZC. Utility of VEGF and sVEGFR-1 in bronchoalveolar lavage fluid for differential diagnosis of primary lung cancer. Asian Pacific journal of cancer prevention. 2013;14(4):2443-6.

11. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013 Dec;13(12):871–882

    ıtus-Lewintre E, Sanmartín E, Sirera R, Blasco A, Sanchez JJ, Tarón M, ѕell R, Camps C. Combined VEGF-A and VEGFR-2 concentrations in ѕma: diagnostic and prognostic implications in patients with advanced CLC. Lung Cancer. 2011 Nov 1;74(2):326-31.

13. Anwar Jusuf AW, Aziza G Icksan, Elisna Syahruddin, Juniarti, Sutjahjo Endardjo. Kanker Paru Jenis Karsinoma Bukan Sel Kecil : Pedoman Diagnosis dan Penatalaksanaan di Indonesia: Perhimpunan Dokter Paru Indonesia; 2015.

14. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. *Ann Glob Heal*. 2019;85(1):1-16. doi:10.5334/aogh.2419.

15. National T, Cancer C. Non-Small Cell Lung. *Cancer*. Published online 2022. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

16. Rasmin M, Jusuf A, Yunus F, et al. *Buku Ajar Pulmonologi Dan Kedokteran Respirasi*. Buku 2. UI Publishing; 2018.

17. The Global Cancer Observatory. Cancer Incident in Indonesia. *Int Agency Res Cancer*. 2020;858:1-2. https://gco.iarc.fr/

18. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK (eds). SEER Cancer Statistics Review 1975-2013 National Cancer Institute SEER Cancer Statistics Review 1975-2013 National Cancer Institute. *SEER Cancer Stat Rev 1975-2013, Natl Cancer Institute Bethesda, MD, http//seer.cancer.gov/csr/1975_2013/, based Novemb 2015 SEER data submission, posted to SEER web site, April 2016*. Published online 2016:1992-2013. http://seer.cancer.gov/csr/1975%7B_%7D2013/results%7B_%7Dmerged/sect%7B_%7D24%7B_%7Dstomach.pdf

19. Ford DW, Koch KA, Ray DE, Selecky PA. Palliative and end-of-life care in lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. *Chest*. 2013;143(5 SUPPL):e498S-e512S. doi:10.1378/chest.12-2367

20. Indonesia KKR, Indonesia PDSOR, Indonesia IAPA, Fisik PDSK, Indonesia R. Pedoman Nasional Pelayanan Kedokteran Kanker Paru. *Jakarta Kementeri Kesehat Republik Indones*. Published online 2016:1-3.

21. Weston A, Harris CC. Multistage Carsinogenesis. Holland-Frei Cancer Medicine 6th Edition. 2003.

22. Soeroso N, Tarigan SP. Faktor Risiko dan Patogenesis: Kanker Paru Diagnosis dan Penatalaksanaan. USU Press. 2017.

23. Domagala-Kulawik J, Osinska I, Hoser G. Mechanisms of immune response regulation in lung cancer. *Transl Lung Cancer Res*. 2014;3(1):15-22. doi:10.3978/j.issn.2218-6751.2013.11.03

z IP. Tumor-Microenvironment Interactions. In: Dalgleish AG, Haefner B, ;. *The Link Between Inflamation and Cancer*. Volumen 13. Springer; )6:125-140. doi:https://doi.org/10.1007/0-387-26283-0_6

25. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT, The 8th Edition Lung Cancer Stage Classification, CHEST (2016), doi: 10.1016/j.chest.2016.10.010.

26. West H, Jin JO. Performance Status in Patients With Cancer. *JAMA Oncol.* 2015;1(7):998. doi:10.1001/jamaoncol.2015.3113

27. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature medicine. 2003 Jun 1;9(6):669-76.

28. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies genes. Genes Cancer, 2011, 2(12):1097–1105.

29. Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL, Mihu CM. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018 Jan 1;59(2):455-67.

30. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond), 2005, 109(3):227–241.

31. Tuomas Tammela and others, The biology of vascular endothelial growth factors, *Cardiovascular Research*, Volume 65, Issue 3, February 2005, Pages 550–563, https://doi.org/10.1016/j.cardiores.2004.12.002

32. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol, 2006, 39(5):469–478.

33. Hanahan D, weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

34. Kajdaniuk D, Marek B, Foltyn w, Kos-Kudła B (2011) vascular endothelial growth factor (veGF)—part 2: in endocrinology and oncology. endokrynol Pol 62(5):456–464

35. Frezzetti D, Gallo M, Maiello MR, D'Alessio A, Esposito C, Chicchinelli N, Normanno N, De Luca A. VEGF as a potential target in lung cancer. Expert Opinion on Therapeutic Targets. 2017 Oct 3;21(10):959-66.

36. Belani CP, Goss G, Blumenschein G Jr (2012) Recent clinical developments and rationale for combining targeted agents in non- small cell lung cancer (NSClC). Cancer treat Rev 38(3):173–184

37. Kubota Y (2012). Tumor Angiogenesis and Anti-angiogenic Therapy. Keio J Med 61(2):47–56

ən T, Zhou F, Jiang W, Mao R, Zheng H, Qin L, et al. Age at diagnosis is eterogeneous factor for non-small cell lung cancer patients. J Thorac Dis ernet]. 2019 Jun 1 [cited 2024 Mar 14];11(6):2251–66. Available from: ɔs://jtd.amegroups.org/article/view/29501/html

39. Putra DH, Wulandari L, Mustokoweni S. Profil Penderita Kanker Paru Karsinoma Bukan Sel Kecil (KPKBSK) Di RSUD Dr. Soetomo. *JUXTA J Ilm Mhs Kedokt Univ Airlangga*. 2016;8(1):30-34.

40. Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M, Dzięgiel P. Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. *Cancers (Basel)*. 2021;13(18). doi:10.3390/cancers13184705

41. de Groot P, Munden RF. Lung Cancer Epidemiology, Risk Factors, and Prevention. *Radiol Clin*. 2012;50(5):863-876. doi:10.1016/j.rcl.2012.06.006

42. Löfling L, Karimi A, Sandin F, Bahmanyar S, Kieler H, Lambe M, et al. Clinical characteristics and survival in non-small cell lung cancer patients by smoking history: a population-based cohort study. Acta Oncol (Madr) [Internet]. 2019 Nov 2 [cited 2024 Mar 14];58(11):1618–27. Available from: https://www.tandfonline.com/doi/abs/10.1080/0284186X.2019.1638521

43. Zhang B, Zhang L, Yue D, et al. Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis. *Transl Lung Cancer Res*. 2020;9(4):1187.

44. Visbal AL, Williams BA, Nichols FC, et al. Gender differences in non–small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. *Ann Thorac Surg*. 2004;78(1):209-215. doi:https://doi.org/10.1016/j.athoracsur.2003.11.021

45. Sagerup CMT, Småstuen M, Johannesen TB, Helland Å, Brustugun OT. Sex-specific trends in lung cancer incidence and survival: a population study of 40 118 cases. *Thorax*. 2011;66(4):301 LP - 307. doi:10.1136/thx.2010.151621

46. Jose NK, Soman B, Thulaseedharan J V., Varghese BT, Thomas S, Tom JJ, et al. Demographic and clinical characteristics of primary lung cancer patients in Kerala: Analysis of data from six teaching centers. J Fam Med Prim Care [Internet]. 2023 Oct [cited 2024 Mar 14];12(10):2501–6. Available from:https://journals.lww.com/jfmpc/fulltext/2023/12100/demographic_and_clinical_characteristics_of.50.aspx

47. Furrukh M. Tobacco smoking and lung cancer: perception-changing facts. *Sultan Qaboos Univ Med J*. 2013;13(3):345.

48. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies. *Int J cancer*. 2012;131(5):1210-1219. **48**

49. Tarigan SP, Soeroso NN, Tumanggor CAK, Gani S, Pradana A. Clinical ofile of Male Patients with Non-Small Cell Lung Cancer in Adam Malik neral Hospital, Medan, Indonesia. Open Access Maced J Med Sci ernet]. 2019 Aug 8 [cited 2024 Mar 16];7(16):2612. Available from: ıc/articles/PMC6876815/

ida F, Sinaga Y, Oktobiannobel J, Ariza R, Soemarwoto S, Progresivitas

G, et al. Description Of Progressivity And Prognosis In Lung Cancer Patients In Rsud. Dr. H. Abdul Moeloek Lampung, 2018-2021. Med Prof J Lampung [Internet]. 2022 Aug 13 [cited 2024 Mar 17];12(2):336–41. Available from: https://www.journalofmedula.com/index.php/medula/article/view/366

51. Zhu D, Ding R, Ma Y, Chen Z, Shi X, He P. Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China. BMC Cancer [Internet]. 2021 Dec 1 [cited 2024 Mar 16];21(1):1–11. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08272-y

52. Xing PY, Zhu YX, Wang L, Hui ZG, Liu SM, Ren JS, et al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. Cancer Med [Internet]. 2019 Jul 1 [cited 2024 Mar 15];8(8):4055. Available from: /pmc/articles/PMC6639195/

53. Digumarthy SR, Mendoza DP, Zhang EW, Lennerz JK, Heist RS. Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. Cancers 2019, Vol 11, Page 2033 [Internet]. 2019 Dec 17 [cited 2024 Mar 15];11(12):2033. Available from: https://www.mdpi.com/2072-6694/11/12/2033/htm

54. Biciuşcă V, Popescu IAS, Traşcă DM, Olteanu M, Stan IS, Durand P, et al. Diagnosis of lung cancer by flexible fiberoptic bronchoscopy: a descriptive study. Rom J Morphol Embryol [Internet]. 2022 Apr 1 [cited 2024 Mar 25];63(2):369. Available from: /pmc/articles/PMC9804073/

55. Walter FM, Rubin G, Bankhead C, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. *Br J Cancer*. 2015;112(1):S6-S13. doi:10.1038/bjc.2015.30

56. Bahl A, Sharma DN, Julka PK, Rath GK. Chemotherapy related toxicity in locally advanced non-small cell lung cancer. *J Cancer Res Ther*. 2006;2(1):14.

57. White SC, Anderson H, Jayson GC, Ashcroft L, Ranson M, Thatcher N. Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. *Ann Oncol*. 2000;11(2):201-206. doi:https://doi.org/10.1023/A:1008328605413

58. Lai Y, Wang X, Zeng T, Xing S, Dai S, Wang J, et al. Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer. J Cancer [Internet]. 2018 [cited 2024 Mar 17];9(9):1538. Available from: /pmc/articles/PMC5950582/

59. Dai M, Hua C, Wang M, Gao L, Jiang L, Liu Y. Targeting regulation of VEGF BPTF in non-small cell lung cancer and its potential clinical significance. J Med Res [Internet]. 2022 Dec 1 [cited 2024 Mar 17];27(1):1–12. ailable from: s://eurjmedres.biomedcentral.com/articles/10.1186/s40001-022-00935-

60. Xu C, Zou J, Li L, Yuan Q, Wang W. Elevated serum Cripto-1 and VEGF levels in patients with non-small cell lung cancer. FASEB BioAdvances [Internet]. 2022 Aug 1 [cited 2024 Mar 18];4(8):539. Available from: /pmc/articles/PMC9353448/

61. Lin Q, Guo L, Lin G, Chen Z, Chen T, Lin J, et al. Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer. Cancer Epidemiol. 2015 Aug 1;39(4):539–44.

62. Zou M, Zhang B, Shi L, Mao H, Huang Y, Zhao Z. Correlation of MRI quantitative perfusion parameters with EGFR, VEGF and EGFR gene mutations in non-small cell cancer. Sci Rep [Internet]. 2024 Dec 1 [cited 2024 Mar 18];14(1). Available from: https://pubmed.ncbi.nlm.nih.gov/38396128/

63. Lee S, Kang HG, Choi JE, Lee JH, Kang HJ, Baek SA, et al. The Different Effect of VEGF Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer according to Tumor Histology. J Korean Med Sci [Internet]. 2016 [cited 2024 Mar 18];31(11):1735. Available from: /pmc/articles/PMC5056204/

64. Bremnes, Roy M.; Camps, Carlos; Sirera, Rafael. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. *Lung cancer*, 2006, 51.2: 143-158.

65. Meyer, Keith C.; Cardoni, Andrew; Xiang, Zhu-Zai. Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. *Journal of Laboratory and Clinical Medicine*, 2000, 135.4: 332-338.

66. Zhao, Hui-liu, et al. Relationship between vascular endothelial growth factor-2578C> a gene polymorphism and lung cancer risk: a meta-analysis. *BMC medical genetics*, 2020, 21: 1-7.